RM-055 / Revolution Medicines - LARVOL DELTA

Revolution Medicines Approaches Pivotal 2026 Clinical Milestones (AD HOC NEWS) - “The most anticipated near-term event is the outcome of the Phase III RASolute 302 trial. This study is evaluating Daraxonrasib in patients with previously treated PDAC. Management has scheduled the release of the crucial top-line results for the first six months of 2026….Furthermore, the initiation of the first human clinical trial for a third compound, RM-055, is planned by the end of 2026.”

First-in-human • New trial • P3 data: top line • Pancreatic Ductal Adenocarcinoma • Solid Tumor